Islet autoantibodies as potential markers for disease recurrence in clinical islet transplantation

Summary:

At present, indications for clinical islet transplantation exist almost exclusively in type-1 diabetic patients with end-stage renal disease receiving the islets either simultaneously with or after an already established kidney graft. This implies, that islet transplantation is performed in type-1 diabetic patients with long disease duration. The fate of the islet allograft is determined by a combination of immunological effector mechanisms. Beside early non-specific inflammation and alloreactivity, chronic autoimmunity may contribute to islet graft failure. The immunologic characterization of the prediabetic state has considerably progressed, whereas, the nature of autoimmunity years and decades after the onset of diabetes is largely unknown. Islet autoantibodies as surrogate markers for islet autoimmunity are well established in prediabetic periods of type-1 diabetes. In contrast, only few data exists in the setting of long-term type-1 diabetic patients undergoing islet transplantation. This article reviews the original data from the Giessen islet transplantation project and the pertinent literature with respect to islet autoimmunity and disease recurrence. It is demonstrated, that autoimmunity may persist in an individual with type-1 diabetes for decades after diabetes onset and that autoimmune responses to transplanted islets are resistent to the immunosuppressive drugs currently used. It is suggested from pilot trials, that type-1 diabetic patients with persistent autoantibodies and individuals, in whom autoantibodies become detectable after the transplantation are at higher risk for early islet graft failure potentially due to recurrent autoreactivity directed to the islet graft.

Abbreviations: GADA glutamic acid decarboxylase antibodies; anti-IA-2ic abs antibodies to the intracytoplasmic domain of protein tyrosine phosphatase IA-2; ICA islet cell antibodies; IAK islet after kidney; SIK simultaneous islet and kidney; NOD-mouse nonobese diabetic mouse; CsA cyclosporin-A; JDF Juvenile Diabetes Foundation; vs. versus; MMF mycophenolate-mofetil.

Autoantibodies - islet transplantation - disease recurrence - autoimmunity - alloimmunity

References

• 1 Atkinson M A, Maclaren N K. The pathogenesis of insulin dependent diabetes.  N Engl J Med. 331 1428-1436 1994; 
• 2 Bach J F. Insulin dependent diabetes as an autoimmune disease.  Endocr Rev. 14 516-542 1994; 
• 3 Bartlett S T, Chin T, Dirden B, Quereshi A, Hadley G. Inclusion of peripancreatic lymph node cells prevents recurrent autoimmune destruction of islet transplants: evidence of donor chimerism.  Surgery. 118 392-397 1995; 
• 4 Bonifacio E, Genovese S, Braghi S, Bazzigaluppi E, Lampasona V, Bingley P J, Rogge L, Pastore M R, Bognetti E, Bottazo G F, Gale E AM, Bosi E. Islet autoantibody markers in IDDM: risk assessment strategies yielding high sensitivity.  Diabetologia. 38 816-822 1996; 
• 5 Braghi S, Bonifacio E, Secchi A, Di Carlo V, Pozza G, Bosi E. Modulation of humoral islet autoimmunity by pancreas allotransplantation influences allograft outcome in patients with type 1 diabetes.  Diabetes. 49 218-224 2000; 
• 6 Brooks-Worrell B M, Peterson K P, Peterson C M, Palmer J P, Jovanovic L. Reactivation of type 1 diabetes in patients receiving human fetal pancreatic tissue transplants without immunosuppression.  Transplantation. 69 166-172 2000; 
• 7 Bretzel R G. Biological alternatives to insulin therapy.  Exp Clin Endocrinol Diabetes 107 ((Suppl 2)) 839-843 1999; 
• 8 Bretzel R G, Brandhorst D, Brandhorst H, Eckhard M, Ernst W, Friemann S, Rau W, Weimar B, Rauber K, Hering B J, Brendel M D. Improved survival of intraportal pancreatic islet cell allografts in patients with type-1 diabetes mellitus by refined peritransplant management.  J Mol Med. 77 140-143 1999; 
• 9 Canadian-European Randomized Control Trial Group . Cyclosporin-induced remission of IDDM after early intervention: association of 1 yr of cyclosporin treatment with enhanced insulin secretion.  Diabetes. 37 1574-1582 1988; 
• 10 De Filippo G, Carel J C, Boitard C, Bougneres P F. Long-term results of early cyclosporin therapy in juvenile IDDM.  Diabetes. 45 101-104 1996; 
• 11 Esmatjes E, Rodriguez-Villar C, Ricart M J, Casamitjana R, Martorell J, Sabater L, Astudillo E, Fernandez-Cruz L. Recurrence of immunological markers for type-1 (insulin-dependent) diabetes mellitus in immunosuppressed patients after pancreas transplantation.  Transplantation. 66 128-131 1998; 
• 12 Giannoukakis M, Rudert W A, Robbins P D, Trucco M. Targeting autoimmune diabetes with gene therapy.  Diabetes. 48 2107-2121 1999; 
• 13 Hering B J, Ricordi C. Results, research priorities, and reasons for optimism: Islet transplantation for patients with type 1 diabetes.  Graft. 2 12-27 1999; 
• 14 Jaeger C, Allendörfer J, Hatziagelaki E, Dyrberg T, Bergis K H, Federlin K, Bretzel R G. Persistent GAD 65 antibodies in longstanding IDDM are not associated with residual betacell function, neuropathy or HLA-DR status.  Horm Metab Res. 29 510-515 1997; 
• 15 Jaeger C, Brendel M D, Hering B J, Eckhard M, Bretzel R G. Progressive islet graft failure occurs significantly earlier in autoantibody positive than in autoantibody negative IDDM recipients of intrahepatic islet allografts.  Diabetes. 46 1907-1910 1997; 
• 16 Jaeger C, Hatziagelaki E, Stroedter A, Becker F, Scherer S, Petzoldt R, Federlin K, Bretzel R G. The Giessen-Bad Oeynhausen familiy study: Improved prediction of type-1 diabetes in a low incidence population of relatives using combinations of islet autoantibodies in a dual step model.  Exp Clin Endocrinol Diabetes. 107 496-505 1999; 
• 17 Jaeger C, Hering B J, Dyrberg T, Federlin K, Bretzel R G. Islet cell antibodies and GAD 65 antibodies in IDDM patients undergoing kidney and islet after kidney transplantation.  Transplantation. 62 424-426 1996; 
• 18 Mandrup-Poulsen T, Molvig J, Andersen H U, Helqvist S, Spinas G A, Munck M. the Canadian-European Randomized Control Trial Group . Lack of predictive value of islet cell antibodies, insulin antibodies and HLA-DR phenotype for remission in cyclosporin-treated IDDM patients.  Diabetes. 39 204-210 1990; 
• 19 Petersen J S, Dyrberg T, Karlsen A E, Molvig J, Michelsen B, Nerup J, Mandrup-Poulsen T. the Canadian-European Randomized control Trial Group . Glutamic acid decarboxylase (GAD 65) autoantibodies in prediction of β-cell function and remission in recent-onset IDDM after cyclosporin treatment.  Diabetes. 43 1291-1296 1994; 
• 20 Roep B O, Stobbe I, Duinkerken G, van Rood J J, Lernmark A, Keymeulen B, Pipeleers D, Claas F HJ, de Vries R RP. Auto- and alloimmune reactivity to human islet allografts transplanted into type-1 diabetic patients.  Diabetes. 48 484-490 1999; 
• 21 Roll U, Ziegler A. Combined antibody screening for improved prediction of IDDM-Modern strategies.  Exp Clin Endocrinol Diabetes. 105 1-14 1997; 
• 22 Savola K, Sabbah E, Kulmala P, Vähäsalo P, Ilonen J, Knip M. Autoantibodies associated with type-1 diabetes mellitus persist after diagnosis in children.  Diabetologia. 41 1293-1297 1998; 
• 23 Schwartz R S. The new immunology-the end of immunosuppressive drug therapy?.  N Engl J Med. 340 1754-1756 1999; 
• 24 Sibley R K, Sutherland D ER, Goetz F, Michael A F. Recurrent diabetes mellitus in the pancreas iso and allograft: A light and electron microscopic and immunohisto-chemical analysis of four cases.  Lab Invest. 53 132-144 1985; 
• 25 Stegall M D, Lafferty K J, Kam I, Gill R G. Evidence of recurrent autoimmunity in human allogeneic islet transplantation.  Transplantation. 63 1272-1274 1996 b; 
• 26 Stegall M D, Lobermann Z, Ostrowska A. Autoimmune destruction of islet grafts in the NOD mouse is resistant to 15-deoxyspergualin but sensitive to anti-CD4 antibody.  J Surg Res. 64 156-160 1996 a; 
• 27 Sundkvist G, Tyden G, Karlsson F A, Bolinder J. Islet autoimmunity before and after pancreas transplantation in patients with type-1 diabetes mellitus.  Diabetologia. 41 1532-1534 1998; 
• 28 Terada M, Salzer M, Lennartz K, Mullen F. The effect of H2 compatibility on pancreatic beta cell survival in the nonobese diabetic mouse.  Transplantation. 45 622-627 1988; 
• 29 Thivolet Ch, Abou-Amara S, Martin X, Lefrancois N, Petruzzo P, McGregor B, Bosshard S, Dubernard J M. Serological markers of recurrent beta cell destruction in diabetic patients undergoing pancreatic transplantation.  Transplantation. 69 99-103 2000; 
• 30 Tyden G, Reinholt F P, Sundkvist G, Bolinder J. Recurrence of autoimmune diabetes mellitus in recipients of cadaveric pancreatic grafts.  N Engl J Med. 335 860-863 1996; 
• 31 Wang Y, McDuffie M, Nomikos I N, Hao L, Lafferty K J. Effect of cyclosporin on immunologically mediated diabetes in nonobese diabetic mice.  Transplantation. 46 1018-1068 1988; 
• 32 Yoon J W, Yoon C S, Lim H W, Huang Q Q, Kang Y, Pyun K H, Hirasawa K, Sherwin R S, Jun H S. Control of autoimmune diabetes in NOD mice by GAD expression or suppression in beta cells.  Science. 284 1183-1187 1999;